Electrophoretic deposition (EPD) is an excellent surface coating approach widely investigated for applications ranging from solar cells, batteries, electrochemical capacitors, solid oxide fuel cells, sensors, molecular sieves, corrosion-resistant coatings, and biomedical materials. On the other hand, superhydrophobic (SHPC) surfaces have enticed substantial recent research interest owing to their superb surface properties. Here, we provide a comprehensive review of electrophoretic-deposited SHPC coatings. Concise descriptions of EPD and superhydrophobicity are provided first, followed by a brief mentioning of works reported on electrophoretic-deposited SHPC coatings by one-step or two-step processing (§2.1). The next section (§2.2) delivers a comprehensive description of these reports based on the micro/nanoparticles used. Works reported in specific applications such as anti-corrosion, biomedical, and oil-separation are described in §2.3. Future scopes of research also presented.Gastrulation is a fundamental morphogenetic process in development. In echinoderms with ancestral-type development through feeding larvae, gastrulation involves radially symmetrical invagination of cells around the blastopore. Gastrulation in the seastar Parvulastra exigua, a species with non-feeding larvae deviates from this pattern. Microinjection of cells with fluorescent lineage tracer dye revealed that early blastomeres contribute unequally to ectoderm and endoderm. In embryos injected at the two-cell stage, asymmetry was evident in the fluorescence at the top of the archenteron and animal pole ectoderm. Archenteron elongation is driven by asymmetrical involution of cells with more cells crossing the blastopore on one side. Lineages of cells injected at the four-cell stage also differed in allocation to endoderm and ectoderm. In embryos injected at the eight-cell stage ectodermal and endodermal fates were evident reflecting the animal and vegetal fates determined by third cleavage as typical of echinoderms. Modification of gastrulation associated with evolution of development in P. exigua shows that this foundational morphogenetic process can be altered despite its importance for subsequent development. However, observations of slight asymmetry in the lineage fates of blastomeres in asterinids with planktotrophic development indicates that gastrulation by asymmetrical involution in P. exigua may be a hypertrophic elaboration of a pre-existing state in ancestral-type development. As for echinoids with lecithotrophic development, involution as a mechanism to contribute to archenteron elongation may be associated with the impact of extensive maternal nutritive reserves on the mechanics of cell movement and a novel innovation to facilitate early development of the adult rudiment.

Chemotherapy related cognitive impairment (CRCI) is a known adverse event that can impact cancer survivors, resulting in long-standing effect on quality of life (QOL) and activities of daily living (ADL). Currently, there is limited knowledge regarding the etiology and therapy for CRCI. Although CRCI following autologous stem cell transplantation (AuSCT) is emerging as a potentially significant concern for patients with underlying haematological malignancies, it is an area that requires further research.

This pilot study assessed 1) the prevalence of CRCI in patients with haematological malignancies both pre-AuSCT and post-AuSCT, 2) the feasibility of a cognitive rehabilitation program (CRP) in survivorship care post-AuSCT.

Over a 12 month period, consecutive patients planned for AuSCT were approached for the study. Enrolled patients were administered a nine-week course of CRP, commencing day 40±5 post-AuSCT. AZD2281 mouse Participants were evaluated using a neuropsychological tool and validated questionnaires at baseline, pre-CRP (day 40±5 post-AuSCT), post-CRP and six months post-CRP.

Thirty-two patients were enrolled. The mean age was 59 years (SD=11.5), 23 (72%) were male and 18 (56%) had multiple myeloma. Participants reported high satisfaction using the CRP, and most devoted significant amount of time as requested.

While there appeared to be a low incidence of significant CRCI in our patient population, the incorporation of CRP in survivorship care appeared to be feasible. A larger randomised study examining the efficacy of CRP should be further explored. This article is protected by copyright. All rights reserved.

While there appeared to be a low incidence of significant CRCI in our patient population, the incorporation of CRP in survivorship care appeared to be feasible. A larger randomised study examining the efficacy of CRP should be further explored. This article is protected by copyright. All rights reserved.VM202 is a plasmid DNA encoding two isoforms of hepatocyte growth factor (HGF). A previous phase II study in subjects with painful diabetic peripheral neuropathy (DPN) showed significant reductions in pain. A phase III study was conducted to evaluate the safety and efficacy of VM202 in DPN. The trial was conducted in two parts, one for 9 months (DPN 3-1) with 500 subjects (VM202 336 subjects; and placebo 164) and a preplanned subset of 101 subjects (VM202 65 subjects; and placebo 36) with a noninterventional extension to 12 months (DPN 3-1b). VM202 or placebo was administered to calf muscles on days 0 and 14, and on days 90 and 104. The primary end point in DPN 3-1 was change from baseline in the mean 24-h Numerical Rating Scale (NRS) pain score. In DPN 3-1b, the primary end point was safety, whereas the secondary efficacy end point was change in the mean pain score. VM202 was well-tolerated in both studies without significant adverse events. VM202 failed to meet its efficacy end points in DPN 3-1. In DPN 3-1b, however, VM202 showed significant and clinically meaningful pain reduction versus placebo. Pain reduction in DPN 3-1b was even greater in subjects not receiving gabapentin or pregabalin, confirming an observation noted in the phase II study. In DPN 3-1b, symptomatic relief was maintained for 8 months after the last injection suggesting that VM202 treatment might change disease progression. Despite the perplexing discrepancy between the two studies, the safety and long-lasting pain-relieving effects of VM202 observed in DPN 3-1b warrant another rigorous phase III study.